Growth Metrics

Pfizer (PFE) Inventory Average (2016 - 2026)

Pfizer has reported Inventory Average over the past 18 years, most recently at $10.7 billion for Q1 2026.

  • Quarterly Inventory Average fell 1.76% to $10.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.7 billion through Mar 2026, down 1.76% year-over-year, with the annual reading at $10.8 billion for FY2025, 4.73% down from the prior year.
  • Inventory Average was $10.7 billion for Q1 2026 at Pfizer, down from $11.1 billion in the prior quarter.
  • Over five years, Inventory Average peaked at $11.6 billion in Q3 2024 and troughed at $9.2 billion in Q4 2022.
  • The 5-year median for Inventory Average is $10.5 billion (2024), against an average of $10.5 billion.
  • Year-over-year, Inventory Average increased 17.15% in 2022 and then fell 2.85% in 2023.
  • A 5-year view of Inventory Average shows it stood at $9.2 billion in 2022, then increased by 10.27% to $10.2 billion in 2023, then increased by 10.69% to $11.3 billion in 2024, then decreased by 1.99% to $11.1 billion in 2025, then dropped by 3.62% to $10.7 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Inventory Average are $10.7 billion (Q1 2026), $11.1 billion (Q4 2025), and $11.6 billion (Q3 2025).